Published in Vaccine Weekly, June 14th, 2006
According to the review, "TNF-alpha is a pivotal cytokine with pleiotropic effects in the innate and adaptive immune systems. Clinically, two strategies have been developed to neutralize it: monoclonal anti-TNF-alpha antibodies and a recombinant protein containing the p75 receptor."
Thierry Martin at INSERM U737 in Strasbourg wrote, "These products have been shown to be remarkably efficacious in the treatment of certain autoimmune and inflammatory conditions, in particular, in rheumatoid arthritis,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.